Telix Pharmaceuticals (ASX:TLX): 3QFY26 Revenue, Imaging Approvals and Clinical Developments

Aditi Sarkar

26 October 2026 03:57 PM AEDT

Telix Pharmaceuticals (ASX:TLX): 3QFY26 Revenue, Imaging Approvals and Clinical Developments

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Telix Pharmaceuticals (ASX:TLX) reported 3QFY26 group revenue of USD 245mn, up 19% YoY.
Precision Medicine revenue reached USD 201mn in 3QFY26, an increase of 30% YoY.
Pixclara entered US commercial use following regulatory approval for glioma imaging.
Telix maintained FY26 revenue guidance of USD 950mn–970mn and revised R&D spending guidance.

Telix Pharmaceuticals Limited develops and commercialises radiopharmaceutical products used in cancer imaging while advancing targeted radiation therapies through clinical trials. Its latest quarterly update reported increased Precision Medicine sales, a newly commercialised brain-cancer imaging product and progress across its clinical portfolio. Shares in Telix Pharmaceuticals (ASX:TLX) closed at AUD 12.94, down 1.90%, after the market session ended on 26 October 2026. The financial and clinical disclosures provide a current account of commercial growth, research expenditure and regulatory priorities.

Company Business

Telix Pharmaceuticals (ASX:TLX) operates across Precision Medicine, Therapeutics and Telix Manufacturing Solutions. Its commercial imaging agents Illuccix and Gozellix are used in positron emission tomography imaging associated with prostate cancer. Pixclara is an imaging agent for glioma, while further diagnostic programs address kidney cancer and other applications.

The business combines product sales with clinical development and manufacturing infrastructure. Manufacturing and pharmacy operations supply radiopharmaceuticals, which require specialised isotope production, handling and distribution. Telix has activities and facilities in Australia, the United States, Europe and Japan, alongside clinical programs conducted internationally.

Recent Development

In October 2026, Telix Pharmaceuticals (ASX:TLX) reported 3QFY26 group revenue of USD 245mn, compared with USD 206mn in the corresponding 2025 quarter. Precision Medicine revenue increased to USD 201mn from USD 155mn, reflecting sales of Illuccix and Gozellix. Telix Manufacturing Solutions generated USD 44mn in third-party revenue, compared with USD 47mn a year earlier.

The company reported that Pixclara received US Food and Drug Administration approval for glioma imaging and that its first commercial doses were administered in September. Enrollment was also completed in the 350-patient BiPASS Phase 3 study evaluating prostate cancer imaging before biopsy. The regulator supported a potential new drug application pathway and granted the program Fast Track designation.

Telix also announced a proposed merger with Isotope Technologies Munich, involving initial consideration of USD 1.65bn on a cash-free, debt-free basis and possible additional contingent payments. The transaction remains subject to shareholder approval and closing conditions. It would combine Telix’s portfolio with additional therapeutic isotope production capabilities and clinical assets.

Financial Performance and Sector Context

For H1FY26, Telix Pharmaceuticals (ASX:TLX) reported revenue of USD 477mn, up 22% YoY from USD 390mn. Gross profit was USD 260mn, compared with USD 209mn in H1FY25. Adjusted EBITDA increased to USD 52mn from USD 21mn, while profit after tax was USD 38mn, compared with a USD 2mn loss.

H1FY26 research and development expenditure totalled USD 124mn. Net operating cash inflow was USD 23mn and cash stood at USD 252mn at 30 June 2026. Profit included USD 40mn of other income from a collaboration agreement, which was separate from commercial product sales. The company also refinanced its convertible bond structure in April.

The October update reaffirmed FY26 revenue guidance of USD 950mn–970mn, with USD 40mn in other income and combined revenue and other income expected to exceed USD 1bn. Telix narrowed its FY26 research and development spending guidance to USD 240mn–260mn. Radiopharmaceutical operations depend on regulatory clearances, isotope availability, specialist production and dependable distribution to treatment and imaging sites.

Risks to Consider

Telix Pharmaceuticals (ASX:TLX) faces regulatory and clinical-development risks, including delays to trials, submissions and marketing authorisations. Its kidney-cancer imaging application for Zircaix requires resubmission following manufacturing-related observations from US regulators. Manufacturing capacity, isotope access, distribution complexity and reimbursement conditions can affect commercial operations. The proposed merger adds financing, integration and approval considerations, while research expenditure remains significant.

What to Watch Next

Relevant milestones for Telix Pharmaceuticals (ASX:TLX) include the planned Zircaix application resubmission, development of the ProstACT Global Phase 3 study and progress in the therapeutic pipeline. The TLX597-Tx Phase 2 OPTIMAL-PSMA study completed enrollment, with a data readout expected in H1FY27. The company is also preparing a Japanese submission for Illuccix and plans to hold a capital markets event in November 2026.

Key Insights

Telix reported year-on-year quarterly revenue growth, greater Precision Medicine sales and expanded commercial activity following the US introduction of Pixclara. H1FY26 results showed positive operating cash flow alongside higher clinical investment. Subsequent disclosures will clarify progress on regulatory filings, trial milestones, 2026 guidance and the conditions attached to the proposed merger.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.